This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis (Tysex)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University of South Florida
ClinicalTrials.gov Identifier:
NCT01455220
First received: October 10, 2011
Last updated: February 14, 2017
Last verified: February 2017
October 10, 2011
February 14, 2017
January 2011
October 2014   (Final data collection date for primary outcome measure)
Sexual Dysfunction (as Measured by the Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ-19) ) [ Time Frame: Baseline, 6 months ]
Change in level of dysfunction demonstrated by the comparison and analysis of Multiple Sclerosis Intimacy and Sexuality Questionnaire (MSISQ-19) responses at end of study to baseline. Minimum score of 19 to maximum score of 95, the higher score indicates a greater level of sexual dysfunction. Primary subscale (min 5 to max 25), Secondary subscale (min 9 to max 45), tertiary subscale (min 5 to max 25), subscale scores are summed for overall total score.
Sexual Dysfunction [ Time Frame: Baseline, 6 months ]
Decrease in level of dysfunction demonstrated by the comparison and analysis of MSISQ-19 responses at end of study to baseline
Complete list of historical versions of study NCT01455220 on ClinicalTrials.gov Archive Site
  • Sexual Function (as Measured by the Multiple Sclerosis Quality of Life (MSQOL-54)) [ Time Frame: Baseline, 6 months ]
    Change in composite score in the sexual function subscale of the Multiple Sclerosis Quality of Life (MSQOL-54) over 6 months of Natalizumab treatment. Minimum score of 0 and max score of 100. A higher score indicates a more positive outcome (less sexual dysfunction).
  • Health Related Quality of Life (as Measured by the Functional Assessment of MS (FAMS)) [ Time Frame: Baseline, 6 months ]
    Change in score on the Functional Assessment of MS (FAMS) questionnaire.The FAMS consists of 44 scored items in six quality-of-life domains: Mobility (seven items), Symptoms (seven items), Emotional well being (seven items), General contentment (seven items), Thinking/fatigue (nine items), and Family/social well being (seven items). Minimum score of 0 to max score of 176. A higher scores indicates positive (better) functional health related quality.
  • Quality of Life (as Measured by the Multiple Sclerosis Quality of Life (MSQOL-54)) [ Time Frame: Baseline, 6 months ]
    Change in score on the Multiple Sclerosis Quality of Life (MSQOL-54) from end of study compared to baseline. The MSQOL-54 is a 54-item quality of life questionnaire that has general, as well as, MS specific questions covered in 6 sub-categories (mobility, symptoms, emotional well-being, general contentment, thinking and fatigue, family/social well-being). Minimum score of 0 to maximum score of 100. Overall quality of life is calculated by averaging question 53 and 54. The sub-scales( mental and physical health) are on a weighted scale. Sets of questions are totaled and divided by the number of questions in each section then that section total is multiplied by a weighted value. Then all weighted values are summed for all relevant question sections for that subscale to compute a composite score for both mental health and physical health. A higher score, indicates a higher perceived quality of life for the patient. A lower scorer indicates poorer quality of life impacted by MS.
  • Sexual Function [ Time Frame: Baseline, 6 months ]
    • Change in composite score in the sexual function subscale of the MSQOL-54 over 6 months of Natalizumab treatment
    • Improvement shown in at least one area designated in the MSISQ-19
  • Fatigue [ Time Frame: Baseline, 6 months ]
    Improved score on the FAMS questionnaire fatigue scale for MS
  • Quality of Life [ Time Frame: Baseline, 6 months ]
    • Improved score on the MSQOL-54 from end of study compared to baseline
    • Improvement shown in the sexual function component of the MSQOL-54
Not Provided
Not Provided
 
The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis
The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis
The purpose of this study is to determine if sexual dysfunction symptoms and quality of life measures in patients with Multiple Sclerosis may be improved in patients that are prescribed Tysabri.
Patients will be naive to Tysabri at the baseline for this study then their sexual dysfunction, fatigue, and quality of life measures will be measured using scaled questionnaires.
Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Multiple Sclerosis
Drug: Tysabri ® (Natalizumab)
IV, monthly
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
45
October 2014
October 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Must give written informed consent and provide all authorizations required by local law(ex. Protected Health Information, PHI)
  2. Minimum baseline score of 15 for the primary sexual dysfunction subscale of the MSISQ-19 (questions 12,16,17,18,19)
  3. Men and Women between 18 and 60 years of age
  4. Must have EDSS less than or equal to 5.5 at baseline
  5. Must be able to walk at least 100m without assistive devices
  6. Must have a documented diagnosis of a relapsing remitting form of MS as defined by the revised McDonald Committee criteria (Polman et al.,2005)
  7. Must have a recent MRI (within 1 year from baseline)
  8. Must satisfy the locally approved therapeutic indications for TYSABRI
  9. Must be stable in disability for at least 30 days prior to enrollment to the study
  10. Must be Natalizumab naïve
  11. Must be stable in symptomatic management of the disease, for at least 30 days prior to enrollment in the study
  12. Must be on a stable regimen of all symptomatic medications for Multiple Sclerosis especially those that could interfere with sexual function (specifically anti-cholinergics, anti-hypertensives, etc.) for at least 30 days prior to the enrollment.
  13. Must be considered by the Investigator to be free of signs and symptoms suggestive of PML based on medical history, physical examination, or laboratory testing.
  14. Must be willing to discontinue and remain free from concomitant immunosuppressive or immunomodulatory treatment (including IFN and GA) while being treated with Natalizumab during the study

Exclusion Criteria:

  1. Must give written informed consent and provide all authorizations required by local law(ex. Protected Health Information, PHI)
  2. Minimum baseline score of 15 for the primary sexual dysfunction subscale of the MSISQ-19 (questions 12,16,17,18,19)
  3. Men and Women between 18 and 60 years of age
  4. Must have EDSS less than or equal to 5.5 at baseline
  5. Must be able to walk at least 100m without assistive devices
  6. Must have a documented diagnosis of a relapsing remitting form of MS as defined by the revised McDonald Committee criteria (Polman et al.,2005)
  7. Must have a recent MRI (within 1 year from baseline)
  8. Must satisfy the locally approved therapeutic indications for TYSABRI
  9. Must be stable in disability for at least 30 days prior to enrollment to the study
  10. Must be Natalizumab naïve
  11. Must be stable in symptomatic management of the disease, for at least 30 days prior to enrollment in the study
  12. Must be on a stable regimen of all symptomatic medications for Multiple Sclerosis especially those that could interfere with sexual function (specifically anti-cholinergics, anti-hypertensives, etc.) for at least 30 days prior to the enrollment.
  13. Must be considered by the Investigator to be free of signs and symptoms suggestive of PML based on medical history, physical examination, or laboratory testing.
  14. Must be willing to discontinue and remain free from concomitant immunosuppressive or immunomodulatory treatment (including IFN and GA) while being treated with Natalizumab during the study
Sexes Eligible for Study: All
18 Years to 60 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01455220
US-TYS-10-10057
No
Not Provided
Plan to Share IPD: No
University of South Florida
University of South Florida
Not Provided
Principal Investigator: Tuan Vu, MD University of South Florida
University of South Florida
February 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP